Drugs in MeSH Category Anesthetics, Inhalation

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Baxter Hlthcare	ETHRANE	enflurane	LIQUID;INHALATION	017087-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Hospira	HALOTHANE	halothane	LIQUID;INHALATION	083254-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Piramal Critical	ENFLURANE	enflurane	LIQUID;INHALATION	074396-001	Jul 29, 1994		DISCN	No	No
Baxter Hlthcare	FORANE	isoflurane	LIQUID;INHALATION	017624-001	Approved Prior to Jan 1, 1982	AN	RX	Yes	Yes
Hospira	ISOFLURANE	isoflurane	LIQUID;INHALATION	074097-001	Jan 25, 1993		DISCN	No	No

Market dynamics and patent landscape for NLM MeSH class “Anesthetics, Inhalation”

Last updated: April 25, 2026

What does the inhaled anesthetics market look like and where is value moving?

Core use-cases

• Surgery/anesthesia induction and maintenance in hospital and ambulatory surgery centers.
• Adjunct airway and procedural anesthesia where inhaled agents support rapid titration, mask induction, and maintenance.

Demand drivers

• Procedure volume (elective surgery cycles and case mix) drives consumption more than new patient starts.
• OR utilization and drug spend controls shape formulary decisions and drive price sensitivity.
• Workforce standardization favors predictable delivery and established dosing profiles, which can slow adoption of incremental entrants.

Value pools inside inhaled anesthetics

• High-volume base agents (commonly used volatile anesthetics) anchor demand and set pricing floors.
• “Rescue” and niche settings (patients with specific contraindications, supply disruptions, or institutional preferences) can shift utilization across agents.
• Delivery systems (vaporizers, anesthesia machine compatibility, calibration services) create stickiness and reduce switching.

Commercial dynamics that impact patent value

• Generic and supplier churn risk: many inhaled agents have mature chemistry and long manufacturing familiarity, raising generic or alternative-supplier threats post-expiry.
• Regulatory and label-change cycles: patent value concentrates in patent-protected formulations, delivery improvements, or new routes/uses that survive generic substitution.
• Supply reliability: periods of supply constraint can increase short-term pricing power for currently marketed products, but these gains rarely extend beyond the product’s patent shelf life.

How is the patent landscape structured for inhaled anesthetics?

Patent portfolios for inhaled anesthetics typically fall into four layers:

1. Active ingredient patents
   Usually expired or close for long-established volatile agents; they define early innovation eras and are not the main source of current incremental exclusivity.

2. Formulation and composition-of-matter refinements
   Lower-level patenting around stabilizers, impurities, or specific concentrations and manufacturing processes can extend protection for particular marketed SKUs.

3. Delivery-device and method-of-use patents

   • Vaporizer calibration methods
   • Control algorithms
   • Bottle/vapor containment systems
   • Use patterns for induction/maintenance
     These can create “system lock-in” that protects value even when active ingredients face substitution.

4. New therapeutic uses or special populations
   New clinical indications can extend exclusivity where they support a distinct label and market access strategy.

Implication for investors and R&D
The highest probability of sustained exclusivity generally comes from device-linked IP, process IP, and labelable method claims, not from discovery of new volatile chemistries alone.

What are the practical constraints that govern freedom-to-operate in this MeSH class?

FTO risk drivers in inhaled anesthetics

• Multi-jurisdiction filings: large Pharma and device OEMs file across EP/WO and US, expanding the mapped claim space for systems and control methods.
• Claiming patterns: method claims tied to “administering” inhaled anesthetic at specified parameters can overlap with routine clinical practice and common titration procedures.
• Generics and authorized generics: for mature volatile agents, the major FTO question often becomes whether your product is substitutable, not whether it infringes a specific ingredient claim.
• Device integration: many patents are owned by anesthesia machine and vaporizer ecosystem players; importing a “mechanism of control” can trigger device-method claim overlap.

Which technical levers show up most often in inhaled anesthetic IP?

Technical themes that repeatedly appear in enforceable claim sets

• Dose delivery control
  Claims that define how target concentration is achieved and maintained (control loops, feedback parameters, compensations for environmental or patient factors).

• Stability and impurity profiles
  Claims tied to manufacturing controls or formulations that maintain consistent agent purity and performance.

• Patient-specific dosing protocols
  Algorithms or method claims using patient characteristics to set vaporizer parameters.

• Anesthesia circuit and containment designs
  Interfaces and components that control flow, reduce leaks, or improve agent capture and recirculation.

Where patents tend to survive substitution

• Device and control improvements are harder to “genericize” than the chemical itself.
• Manufacturing-process claims can protect specific product lots and production routes.
• Label-based method claims create a narrower substitute path because they require specific prescribing and procedural context.

How does MeSH “Anesthetics, Inhalation” map to investable patent targets?

Operationally, the MeSH class clusters around

• Volatile agents used for maintenance and induction.
• Inhalation anesthesia delivery technologies.
• Adjunct procedural uses involving inhaled anesthetic administration.

Investable patent target categories

• Formulation and manufacturing that supports consistent pharmacokinetics and reduced impurities.
• Vaporizer control systems that reduce delivered concentration error.
• Anesthesia workflow methods that integrate dosing, monitoring, and safety thresholds.
• Circuit architecture designed to reduce waste, scavenging loss, or contamination.

What does the patent landscape imply for market entry timing?

Near-term entry strategy

• For mature volatile agents, entry typically relies on:
  • Approved product access (through regulatory routes and supply capability)
  • Differentiation via device integration or specific formulation/process IP not yet expired
  • Contracts that secure institutional adoption

Mid-horizon strategy

• Target system-level IP with longer runway:
  • Control algorithms and monitoring workflows
  • Circuit improvements with measurable efficiency and safety benefits
  • New label-expansion routes if clinical data supports it

Late-stage strategy

• Focus on post-launch protection:
  • Continuations tied to process improvements
  • New claims around refinements of delivery and monitoring

Where are the key “patent vs market” friction points?

1. Substitutability
   If clinicians can switch between inhaled agents with similar clinical outcomes, patent-based price premiums compress rapidly after generic entry.

2. Device dependency
   Systems may require specific calibrations, sensors, or circuit configurations. Patents here can outlast ingredient patents.

3. Procurement and formularies
   Hospitals often renegotiate on total cost, supply reliability, and service agreements, which affects how long patent exclusivity converts to pricing power.

4. Supply chain events
   Manufacturer disruptions can temporarily shift volumes. Patent exclusivity does not automatically translate into sustained capture if supply constraints are resolved for competing SKUs.

What data-backed approach should be used to assess patent barriers in this MeSH class?

Patent landscape workflow for inhaled anesthetics

• Claim-type filtering
  Separate ingredient claims from formulation/process and from device-method claims.
• Assignee mapping
  Map claim ownership across:
  • Pharmaceutical product owners
  • Device OEMs and controls providers
  • Hospital systems (where method protocols get claimed)
• Expiration and continuation tracking
  Track:
  • earliest non-provisional filing
  • patent term adjustments (where applicable)
  • continuations that broaden claim scope without changing core product position
• Product-to-claim linkage
  Identify whether your planned product is a match on:
  • concentration/impurities and manufacturing constraints
  • delivery mechanism (controller type, feedback inputs)
  • circuit components and operating method

Business outcome

• The risk is rarely “one patent blocks entry.” The risk is that multiple overlapping weak patents in delivery methods and formulations can raise settlement probability and delay timelines.

---

Key Takeaways

• Inhaled anesthetics value concentrates in hospital standardization, OR workflows, and delivery systems, not only in active ingredient chemistry.
• Patent protection in this MeSH class is most robust in device-linked delivery control, manufacturing/process stability, and labelable method claims.
• Freedom-to-operate risk often comes from system and method claims that map to routine clinical dosing and vaporizer control practices, plus broader device ecosystem patent coverage.
• Market entry hinges on substitutability and procurement dynamics; even with patent exclusivity, pricing power is constrained when alternatives are clinically interchangeable.

---

FAQs

1. Which IP types matter most for inhaled anesthetics if ingredient patents are old or expired?
   Device-linked delivery control, manufacturing/process stability, and method-of-use claims that support a distinct label or dosing protocol.

2. Why do anesthesia machine and vaporizer patents often matter in FTO for drug projects?
   Many enforceable claims target the control logic and integration that governs how inhaled anesthetic concentration is delivered and maintained.

3. Does generic competition typically erode all patent value in this class?
   It erodes active-ingredient value fastest, but system-level and process/formulation protections can still preserve defensible differentiation.

4. What drives hospital adoption even when patents still exist?
   Total cost of ownership, supply reliability, compatibility with existing vaporizer and monitoring workflows, and formulary contracting.

5. Where should diligence focus when assessing whether a project is “clear to market”?
   Claim-type segmentation (ingredient vs delivery vs process), assignee mapping across device ecosystem owners, and expiration/continuation timelines tied to the intended product and delivery method.

---

References

[1] NLM (National Library of Medicine). MeSH Browser. “Anesthetics, Inhalation.” https://meshb.nlm.nih.gov/